華潤雙鶴(600062.SH)子公司注射液產品通過仿製藥質量及療效一致性評價
華潤醫藥(03320.HK)旗下子公司華潤雙鶴(600062.SH)公佈,全資子公司華潤雙鶴利民藥業的克林黴素磷酸酯注射液,近日收到國家藥品監督管理局頒發的《藥品補充申請批準通知書,該產品通過仿製藥質量和療效一致性評價。
集團表示,克林黴素磷酸酯爲克林黴素的衍生物,作爲臨牀常用抗生素,適用於對青黴素過敏或不宜使用青黴素的患者、毒性較低的替代藥(如紅黴素)無法治療的嚴重細菌感染,預期本次通過一致性評價,將更有利於進一步提升產品的市場綜合競爭力及市場銷售份額,對華潤醫藥整體經營業績持續產生積極正面的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.